top of page
Two female researchers demonstrating laboratory and computer work for GET-IN doctoral network

Alia Therapeutics

Beneficiary Partner

Building of beneficiary partner Alia Therapeutics

Alia Therapeutics is working to engineer novel and disruptive CRISPR tools for gene editing. We focus on the discovery of novel microbiome-derived CRISPR nucleases and the development of innovative delivery methods for the treatment of incurable genetic diseases. Our unique discovery platform aims to identify and optimize nucleases derived from the human microbiome  to target specific diseases. Our approach unleashes the full potential of the CRISPR technology and overcomes its main limitations: selectivity, efficacy, flexibility and delivery. Alia was founded in 2018 and received seed financing from Sofinnova Partners, BiovelocITA, the first Italian biotech startup accelerator, and other Italian investors.

GET-IN logo and organisation name

This project has received funding from the European Union’s Framework Programme for Research and Innovation, Horizon Europe under Grant Agreement No. 101119880

ON5b, Herestraat 49, Box 1023

3000 Leuven, Belgium

Follow us on 

  • Linkedin
logos.jpg

©2023 by GET-IN. Made with pride by Websters

Funded by the European Union banner
bottom of page